Navigation Links
Kinase in Medical Technology

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

... of clinical data for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the American Society of ... ) ENMD-2076, a small molecule, oral kinase inhibitor that targets Aurora A and other kinases ... is an orally-active, Aurora A/angiogenic kinase inhibitor with a ...

Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients

... through the PI3K/PTEN pathway. About PI3 kinase Phosphatidylinositol 3 kinases (PI3K) are ... and survival/apoptosis. Dysregulation of the PI3 kinase signaling cascades can lead to cancer and ... focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising ...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

... through the PI3K/PTEN pathway. About PI3 kinase Phosphatidylinositol 3 kinases (PI3K) are ... and survival/apoptosis. Dysregulation of the PI3 kinase signaling cascades can lead to cancer and ... focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising ...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

... 2992, an Irreversible, Dual EGFR / HER2 Tyrosine kinase Inhibitor, Suggests Activity in Second-line ... It is the first irreversible EGFR-TKI (tyrosine kinase inhibitor) to reach Phase III for ... 'activating' mutations that arise in the tyrosine kinase (TK) domain of the EGFR gene are associated with ...

Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

... in clinical development. Bruton's tyrosine kinase is the gene that is disrupted in the ... 2009 8:00 am - 12:00 pm Poster Session kinase Inhibitors 3 Experimental and Molecular ... #3740 A Clinical Trial of the Bruton's Tyrosine kinase (Btk) Inhibitor PCI-32765 in Naturally Occurring ...

Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor

... Resulting from Inhibiting Multiple Pathways) kinase platform by designing a small molecule that was ... SF2626 is the first combination PI3K and MEK kinase inhibitor that, in preclinical studies, blocks ... to rational drug design for combination pathway kinase inhibitors. Semafore's dual ...

Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas

... the efficacy of R788, an orally bio-available Syk kinase inhibitor, in patients suffering from this subset ... in certain types of B-cell lymphomas and that Syk kinase appears to play an important role in certain ... entitled, "An Orally Available Syk Tyrosine kinase Inhibitor Induces Apoptosis in Peripheral T-Cell ...

EntreMed Presents Initial Clinical Results for ENMD-2076

... its program for ENMD-2076, an Aurora A/angiogenic kinase inhibitor. These developments include the ... step forward for our Aurora/angiogenic kinase inhibitor program. With our ongoing trial in ... is an orally-active, Aurora A/angiogenic kinase inhibitor with a ...

Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

... a Phase I clinical trial of its oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced ... of CK2, a constitutively active protein kinase that is overexpressed in a wide range of cancers. ... About CX-4945, an oral CK2 protein kinase inhibitor CX-4945 is a first-in-class small ...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia

... therapies, today announced that its oral PIM kinase inhibitor, SGI-1776, is effective both in vitro ... also reduced tumor burden. "Our PIM kinase inhibitor, SGI-1776, has significant potential in ... It has been postulated that inhibition of PIM kinase may potentiate the activity of m-tor inhibitors ...

S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis

... SB1518 is a small molecule JAK2-selective kinase inhibitor which has high potency against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is ...

Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora

... types of tumour. A lecture focusing on Aurora kinase inhibitors will be presented today by Dr. Bernard ... a presentation on the state-of-the-art of Aurora kinase inhibitors, providing a comprehensive summary of ... capable of inhibiting activity of this kinase family and displaying anti-tumour efficacy in a ...

Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium

... ) TAK-285 and TAK-593 are receptor tyrosine kinase inhibitors. Non-clinical data suggest their ... MLN8237 This Millennium-discovered Aurora A kinase inhibitor currently is being studied in Phase I ... -- MLN8237, an oral selective Aurora A kinase inhibitor: initial results of dose-finding ...

Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement

... Companies to Study B-Raf kinase Inhibitors for Cancer Treatments INDIANAPOLIS, ... related to Deciphera's preclinical B-Raf kinase inhibitor program for the study of potential ... a unique, proprietary approach to kinase inhibitor design, together with Lilly's expertise ...

SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines

... antiangiogenic activity of vascular-targeted PI3 kinase (PI3K) inhibitor SF1126, by blocking both VEGF ... on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising ... biological rationale for developing PI3 kinase inhibitors to treat cancer. Phosphoinositide ...

Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors

... announcing the discovery of novel multi-targeted kinase inhibitors that demonstrate significant ... modeling allowing for the design of pan-PI3 kinase inhibitors as well as isoform-selective small molecule PI3 kinase inhibitors. The scaffold also allows for the ...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

... in Copenhagen, Denmark, that its lead, oral PIM kinase inhibitor, SGI-1776, causes tumor regression in ... and MV-4-11 (AML) xenograft models. "Our PIM kinase inhibitor, SGI-1776, has the potential to be ... PIM kinase inhibitor with in vivo oral ...

Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors

... product candidate, SF1126, a targeted pan-PI3 kinase (PI3K) inhibitor, in patients with advanced solid tumors. SF1126 is the first PI3 kinase inhibitor to be evaluated clinically in both ... "As a leader in the clinical development of PI3 kinase inhibitors, we are pleased to announce this ...

Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO

... small molecule inhibitor of phosphoinositide-3 kinase (PI3K) and mTOR, which are implicated in tumor ... in the PI3K signaling pathway. PI3K is a lipid kinase that plays a pivotal role in ... signals in cells, and mTOR is a serine/threonine kinase that controls the protein translation machinery ...

Latest Cell Publication Describes the Novel Kinase Regulators Using OriGene's Functional Kinome Collection

... kinome collection for identification of kinase regulating Hedgehog signaling." The ... of novel regulatory kinases. "The isolated kinase genes form a resource that scientists can now use to systematically map kinase signaling networks in different cellular disease ...

SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models

... Meeting that that it has identified a lead PIM kinase inhibitor, SGI-1776, that causes tumor regression ... allowed for the creation of small molecule PIM kinase inhibitors. SGI-1776 was identified as a ... are encouraged by these promising data. Our PIM kinase inhibitor, SGI-1776, may prove to be a treatment ...

EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting

... an oral presentation on the Company's selective kinase inhibitor, ENMD-2076, during the special session, ... 13, 2008, at 3:15 p.m. ENMD-2076 is selective kinase inhibitor with potent activity against Aurora A ... antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced ...

EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program

... Selective kinase Inhibitor Phase 1 Trial in Advanced Cancer ... Phase 1, dose-escalation study for its selective kinase inhibitor, ENMD-2076, in advanced cancer ... ) ENMD-2076 is a novel, selective kinase inhibitor with potent activity against Aurora A ...

Rigel's R788 Shows Preclinical Activity in Type 1 Diabetes Model

... RIGL ) today announced that its oral Syk kinase inhibitor, R788, may be a useful treatment for ... Medical Center have shown that blocking Syk kinase in a well-established murine model of type 1 ... was also observed. "Inhibition of the Syk kinase has the potential to reduce both autoantibody ...

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting

... p.m. - #4974 -- A potent small molecule PIM kinase April 15 2:40 p.m. inhibitor with ... April 15 receptor tyrosine kinase inhibitor MP-470 ... April 16 selective Aurora A kinase inhibitor, in a ...

Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology

... non-clinical data on SNS-032, a cyclin-dependent kinase (CDK) inhibitor, during poster session ... of Action of SNS-032, a Novel Cyclin Dependent kinase Inhibitor, in Chronic Lymphocytic Leukemia: ... in B-cell malignancies. SNS-314, an Aurora kinase inhibitor, is being studied in a Phase 1 ...

Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2

... associated with carcinogenesis. Several aurora kinase inhibitors are currently under clinical ... of selective small molecule inhibitors of aurora kinase A and B and VEGFR2. Treatment of human colorectal ... data support the continued development of aurora kinase and VEGFR2 inhibitors," said James G. Keck, ...

Data Support use of SuperGen's CLIMB Technology in Lead Development and Optimization

... technology identifies small molecule JAK2 and Pim kinase inhibitors SAN ... design of small molecule JAK2 and Pim kinase inhibitors (Posters C200 and C208). Poster C200 ... 907) Effect of small molecule inhibitors of JAK2 kinase on modulating signaling cascades downstream of ...

PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy

... expression and with reductions in serum creatine kinase values. These data were presented today at the ... also had substantially elevated serum creatine kinase levels due to the disease, and symptoms ... blood analyses to assess muscle-derived creatine kinase were available from all 38 patients. An in vitro ...

New Data for XL880, XL647 and XL184 to Be Presented at AACR-NCI-EORTC

... (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients ... study of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to ... and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor, administered daily to patients ...

Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration

... Phase 2 Clinical Trial Initiated for a p38 kinase Inhibitor Identified through Collaboration with ... in the study. "It is generally accepted that p38 kinase inhibitors could be effective in a range of ... a Phase 1 trial in Canada with a second p38 kinase inhibitor resulting from the ...

S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies

... SB1518 is a small molecule JAK2-selective kinase inhibitor. It has high potency against both the wild type JAK2 kinase and the JAK2 kinase with the activating V617F mutation which is found ...

New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects

... (NMEs) in the drug development pipeline comprise various classes of kinase inhibitors that cause unacceptable toxicity in humans. Proper formulation ... currently, no appropriate formulation technology is available for these kinase inhibitors. This project focuses on a systematic approach in which ...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

... BAY 73-4506 is a dual targeted VEGFR2-TIE2 anti-angiogenic oral tyrosine kinase inhibitor (TKI) with a kinase inhibition profile targeting angiogenic, stromal and oncogenic receptor ...

Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting

... public description of CX-4945, a first-in-class oral inhibitor of protein kinase CK2. CK2 overexpression is well documented in many cancers and represents ... a selective orally bioavailable small molecule inhibitor of protein kinase CK2: Phase I initiated - Experimental and Molecular Therapeutics 34, ...

S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies

... safety profile of SB1518. SB1518 is a small molecule JAK2-selective kinase inhibitor which has high potency against both the wild-type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found ...

Cytopia Appoints Study Chairman for JAK2 Clinical Trial

... for a "best in class" inhibitor. Cytopia is a world leader in JAK2 kinase chemistry and holds a broad range of JAK2 related patents. The main area ... studies. Cytopia also is building on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the ...

Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia

... and decreases in phosphorylation of CrkL are indicative of BCR-ABL kinase inhibition. XL228 also inhibits IGF1R and the insulin receptor, and plasma ... near baseline by 4 hours post-infusion. About XL228 XL228 is a protein kinase inhibitor with potent activity against wild-type and the T315I mutant ...

Cytopia Announces Novel Anti-Cancer Drug Development Collaboration

... This agreement leverages Cytopia's early stage drug discovery pipeline of kinase inhibitors, a class of targeted therapeutics that is one of the fastest ... metastatic cancers. Development of an inhibitor of this particular kinase could have blockbuster potential in the cancer market. Under the project ...

Semafore's PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma

... at the 2008 AACR Annual Meeting that its integrin-targeted PI3 kinase inhibitor, SF1126, was shown to cause significant tumor regression in ... and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple ...
Other Contents
(Date:10/16/2014)... at William and Mary,s Virginia Institute of Marine ... the Environmental Protection Agency to identify the streams ... to develop tools to help local governments and ... depends critically on a dataset of tidal-marsh observations ... Only with this historical baseline can today,s researchers ...
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
(Date:10/22/2014)... 2014 Isabel Healthcare will ... Professions (ASAHP) Conference on October 22-24 in Las Vegas, ... in a panel discussion on Technology in Health Professions ... provides a diagnostic decision support tool and clinical education ... of students and clinical learners. The Isabel tools help ...
(Date:10/22/2014)... The Louis W. Sullivan ... to distribute health information technology innovation to transform ... the development of six key guiding principles of ... healthcare. These are an expansion of the Institute ... that is respectful of and responsive to individual ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... part of conventional in vitro fertilization (IVF) -- the incubation ... place in a device inside the vagina, new research suggests. ... the device, called an INVOcell, might sharply cut costs for ... the technology more accessible to those who don,t live near ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
Other TagsOther Tags